Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Westervelt

Showing results (241-250 of 359) with videos related to

Pageof 36
Sort By:
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host diseasePaul A Carpenter, James Lowder, Laura Johnston, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
American Journal of Hematology|April 12, 2014
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AMLJohn S Welch, Haixia Niu, Geoffrey L Uy, et al.
Leukemia Research|October 7, 2021
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDSEric Huselton, Michael P Rettig, Kirsten Campbell, et al.
JAMA Oncology|August 18, 2016
Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical TrialStephanie J Lee, Brent Logan, Peter Westervelt, et al.
Cureus|March 2, 2022
Reinvigorating an Academy of Medical Educators Using Ecological Systems TheoryEric Zwemer, Fei Chen, Gary L Beck Dallaghan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
The Science of the Total Environment|January 5, 2021
Role of emission controls in reducing the 2050 climate change penalty for PM<sub>2.5</sub> in ChinaSong Liu, Jia Xing, Daniel M Westervelt, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemiaCharles Lu, Peter Riedell, Christopher A Miller, et al.
Pageof 36

Showing results (241-250 of 359) with videos related to

Sort By:
Pageof 36
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 19, 2011
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literatureJ S Chawla, A Ghobadi, J Mosley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 3, 2005
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host diseasePaul A Carpenter, James Lowder, Laura Johnston, et al.
Bone Marrow Transplantation|July 5, 2001
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulinH Khoury, A Kashyap, D R Adkins, et al.
American Journal of Hematology|April 12, 2014
A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AMLJohn S Welch, Haixia Niu, Geoffrey L Uy, et al.
Leukemia Research|October 7, 2021
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDSEric Huselton, Michael P Rettig, Kirsten Campbell, et al.
JAMA Oncology|August 18, 2016
Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical TrialStephanie J Lee, Brent Logan, Peter Westervelt, et al.
Cureus|March 2, 2022
Reinvigorating an Academy of Medical Educators Using Ecological Systems TheoryEric Zwemer, Fei Chen, Gary L Beck Dallaghan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
The Science of the Total Environment|January 5, 2021
Role of emission controls in reducing the 2050 climate change penalty for PM<sub>2.5</sub> in ChinaSong Liu, Jia Xing, Daniel M Westervelt, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemiaCharles Lu, Peter Riedell, Christopher A Miller, et al.
Pageof 36